Novocure Ltd
NVCR12.800USD
-0.020-0.16%
收盘 10/31, 16:00（美东）报价延迟15分钟
1.43B总市值
亏损市盈率 TTM
关于 Novocure Ltd 公司
NovoCure Limited 是一家全球性肿瘤学公司。该公司从事肿瘤治疗场 (TTFields) 设备的开发、制造和商业化，包括用于治疗实体肿瘤癌症的 Optune 和 Optune Lua。其商业化产品在某些国家已获准用于治疗患有胶质母细胞瘤、恶性胸膜间皮瘤和胸膜间皮瘤的成年患者。该公司正在进行关键研究，评估 TTFields 在治疗卵巢癌、非小细胞肺癌 (NSCLC) 脑转移（脑转移）和胰腺癌中的应用。其主要优先事项是推动其商业 TTFields 设备 Optune 的商业化应用。该公司还拥有在中国、香港、澳门和台湾销售 Optune 的许可。该公司正在进行或已完成临床试验，研究肿瘤治疗场在脑转移、胃癌、胶质母细胞瘤、肝癌、非小细胞肺癌、胰腺癌和卵巢癌中的应用。
Novocure Ltd简介
公司代码NVCR
公司名称Novocure Ltd
上市日期Oct 01, 2015
CEOMs. Ashley Cordova
员工数量1488
证券类型Ordinary Share
年结日Oct 01
公司地址No. 4 The Forum
城市SAINT HELIER
上市交易所NASDAQ Global Select Consolidated
国家Jersey
邮编JE2 4UF
电话441534756700
网址https://www.novocure.com/
公司代码NVCR
上市日期Oct 01, 2015
CEOMs. Ashley Cordova
Novocure Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
438.86K
+22.82%
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
86.17K
+30.22%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Mr. Martin J. Madden
Mr. Martin J. Madden
Independent Director
Independent Director
18.67K
-5.08%
Ms. Kristin Stafford
Ms. Kristin Stafford
Independent Director
Independent Director
14.27K
+252.06%
Dr. Allyson Ocean, M.D.
Dr. Allyson Ocean, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
438.86K
+22.82%
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
86.17K
+30.22%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
94.26M
59.36%
Germany
19.07M
12.01%
France
18.42M
11.60%
Other EMEA countries
12.98M
8.17%
Japan
9.48M
5.97%
Greater China
4.59M
2.89%
业务
地区
暂无数据
股东统计
更新时间: 10月2日 周四
更新时间: 10月2日 周四
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.96%
The Vanguard Group, Inc.
9.60%
BlackRock Institutional Trust Company, N.A.
8.04%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
6.18%
其他
53.95%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.96%
The Vanguard Group, Inc.
9.60%
BlackRock Institutional Trust Company, N.A.
8.04%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
6.18%
其他
53.95%
股东类型
持股股东
占比
Investment Advisor
50.51%
Hedge Fund
15.96%
Investment Advisor/Hedge Fund
15.76%
Individual Investor
10.11%
Research Firm
2.21%
Sovereign Wealth Fund
0.87%
Pension Fund
0.59%
Bank and Trust
0.31%
Venture Capital
0.12%
其他
3.57%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
574
97.34M
87.06%
-9.98M
2025Q2
683
107.66M
96.30%
-11.23M
2025Q1
737
108.90M
97.99%
+1.47M
2024Q4
761
104.07M
94.71%
-2.49M
2024Q3
766
105.53M
97.47%
-2.32M
2024Q2
782
105.08M
97.13%
+3.28M
2024Q1
775
93.94M
87.31%
-7.19M
2023Q4
784
94.40M
88.34%
-2.12M
2023Q3
811
96.26M
90.17%
-961.84K
2023Q2
853
95.14M
89.25%
-1.89M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
16.72M
14.96%
+235.48K
+1.43%
Jun 30, 2025
The Vanguard Group, Inc.
10.73M
9.6%
-499.10K
-4.45%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.99M
8.04%
+204.02K
+2.32%
Jun 30, 2025
Wyss (Hansjorg)
8.14M
7.28%
--
--
Apr 04, 2025
Soleus Capital Management, L.P.
6.90M
6.18%
+1.38M
+25.05%
Jun 30, 2025
Capital World Investors
6.38M
5.71%
+1.17M
+22.38%
Jun 30, 2025
BlackRock Financial Management, Inc.
2.73M
2.44%
+665.88K
+32.30%
Jun 30, 2025
State Street Investment Management (US)
2.68M
2.4%
+89.36K
+3.45%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.44M
2.19%
-19.15K
-0.78%
Jun 30, 2025
Balyasny Asset Management LP
2.27M
2.03%
+634.92K
+38.83%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
SPDR S&P Health Care Equipment ETF
1.28%
Global X HealthTech ETF
1.17%
ROBO Global Healthcare Technology & Innovation ETF
1.07%
Amplify BlueStar Israel Technology ETF
0.64%
iShares Health Innovation Active ETF
0.32%
VanEck Israel ETF
0.25%
Global X Aging Population ETF
0.21%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares U.S. Medical Devices ETF
0.14%
查看更多
SPDR S&P Health Care Equipment ETF
占比1.28%
Global X HealthTech ETF
占比1.17%
ROBO Global Healthcare Technology & Innovation ETF
占比1.07%
Amplify BlueStar Israel Technology ETF
占比0.64%
iShares Health Innovation Active ETF
占比0.32%
VanEck Israel ETF
占比0.25%
Global X Aging Population ETF
占比0.21%
ProShares Ultra Nasdaq Biotechnology
占比0.14%
Invesco Nasdaq Biotechnology ETF
占比0.14%
iShares U.S. Medical Devices ETF
占比0.14%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
